JAN. 25, 2018 - "In the fourth quarter we prepared the organization to fully leverage the improved position for Zubsolv® in the US"
CEO Nikolaj Sørensen will give a company update at Redeye´s Investor After Work, February 20. The presentation will focus on the strategic agenda, the positive sales development for Zubsolv in the US, the upcoming European launch and the increased activities in the pipeline.
DECEMBER 12 2017 As the Formulary List of Covered Drugs for 2018 has been announced in the US, Orexo today announces specific information about the improved market access position for Zubsolv® in 2018, earlier communicated in the Q317 report. This progress can mainly be explained by Zubsolv´s preferred position at CVS Caremark and by exclusive contracts with Humana and Envision.